Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial - Studying Acute Exacerbations and Response: The COPD STARR 2 study

niversity of Oxford0 sites228 target enrollmentJune 22, 2017

Overview

No summary available.

Registry

who.int

Start Date

June 22, 2017

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Participant is willing and able to give informed consent for participation in the trial.
•Male or Female, aged 40 years or above.
•Diagnosed with COPD (primary or secondary care diagnosis) with spirometric confirmation of airflow obstruction (FEV1/FVC ratio \<0\.7\).
•A history of at least 1 exacerbation in the previous 12 months, requiring systemic corticosteroids and/or antibiotics.
•Current or ex\-smoker with at least a 10 pack year smoking history
•In the opinion of the research staff, is able and willing to comply with all trial requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 114

•History of atopic childhood asthma
•Current history of primary lung malignancy or current active pulmonary TB
•Clinically relevant disease or disorder (past or present) which in the opinion of the investigator may either put the subject at risk because of participating in the study or may influence the results of the study or the subject’s ability to participate in the study.
•Any clinically relevant lung disease, other than COPD considered by the investigator to be the primary diagnosis. For example mild\-to\-moderate bronchiectasis is acceptable in addition to COPD unless the bronchiectasis is considered to be the primary diagnosis.
•An alternative cause for the increase in symptoms of COPD that are unrelated to an exacerbation such as i) suspicion or clinical evidence of pneumonia; ii) high probability and suspicion of pulmonary embolism; iii) suspicion or clinical evidence of a pneumothorax; iv) primary ischaemic event – ST or Non ST elevation myocardial infarct and left ventricular failure \[i.e. not an exacerbation of COPD]
•A known allergy to the IMP (prednisolone),NIMP (doxycycline) or to any of the constituents of the placebo
•Patients on maintenance corticosteroids (prednisolone, hydrocortisone, fludrocortisone)
•Known adrenal insufficieny
•Currently enrolled in another CTIMP trial and receiving an intervention as part of the trial.
•Pregnant and breast\-feeding women.